Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTRA1 | Q92743 | 15/20 | 0.44 |
| ▸ | STS | P08842 | 2/20 | 0.41 |
| ▸ | MMP1 | P03956 | 2/20 | 0.41 |
| ▸ | MMP9 | P14780 | 2/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP7 | P09237 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19899279 | 1.00 | HTRA1 (0.44) | HTRA1STSMMP1MMP9MMP3 | |
| SCHEMBL19899315 | 0.89 | STS (0.49) | HTRA1STS | |
| SCHEMBL21104741 | 0.89 | STS (0.49) | HTRA1STS | |
| SCHEMBL1373833 | 0.83 | MMP1 (0.41) | STSMMP1MMP9MMP3MMP7 | |
| SCHEMBL2169710 | 0.83 | MMP1 (0.41) | STSMMP1MMP9MMP3MMP7 | |
| SCHEMBL19912650 | 0.82 | STS (0.49) | HTRA1STSMAPT | |
| SCHEMBL19899344 | 0.82 | STS (0.49) | HTRA1STSMAPT | |
| SCHEMBL19912653 | 0.81 | HTRA1 (0.54) | HTRA1 | |
| SCHEMBL21104748 | 0.80 | HTRA1 (0.62) | HTRA1 | |
| SCHEMBL19912652 | 0.80 | HTRA1 (0.62) | HTRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190185426-A1 | NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES AS HTRA1 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-06-20 | — | — | US | disclosed |
| WO-2018036942-A1 | NEW DIFLUOROKETAMIDE DERIVATIVES AS HTRA1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185426-A1 | NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES AS HTRA1 INHIBITORS | HTRA1, HTRA2, HTR1A | HTRA1 1/4885STS 2348/4885MMP1 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.